Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11772230 | 0.89 | CES2 (0.41) | CYP4F2CYP4A11ALDH1A1PPARACFD | |
| SCHEMBL3385017 | 0.86 | ALDH1A1 (0.52) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6511138 | 0.85 | PPARA (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11055698 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27904900 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL27888037 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10396455 | 0.84 | GLA (0.46) | HPGD | |
| SCHEMBL16034181 | 0.84 | CES2 (0.38) | CYP4F2CYP4A11ALDH1A1PPARACFD | |
| SCHEMBL1953516 | 0.83 | CA12 (0.45) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL9222184 | 0.82 | ADRB3 (0.41) | CYP4F2CYP4A11ALDH1A1PPARARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2025-03-06 | — | — | US | disclosed |
| WO-2022098108-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-05-12 | — | — | WO | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-2411365-B1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2344459-B1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | HOFFMANN LA ROCHE (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8450313-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8268820-B2 | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HUNZIKER DANIEL (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8008505-B2 | Indazole or 4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2344459-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. Hoffmann-La Roche AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010108903-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010034649-A1 | 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | DR. REDDY'S LABORATORIES LIMITED | 2004-12-09 | — | — | US | disclosed |
| US-4555516-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | PFIZER INC. (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | CYP4F2 238/4885CYP4A11 71/4885ALDH1A1 317/4885 |
| US-20130172335-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | CYP4F2 158/4885CYP4A11 75/4885ALDH1A1 708/4885 |
| US-20250073218-A1 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | NLRP3, XIAP, NLRP1 | CYP4F2 4289/4885CYP4A11 2437/4885ALDH1A1 3238/4885 |
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | CYP4F2 176/4885CYP4A11 75/4885ALDH1A1 725/4885 |
| US-20120232071-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | CYP4F2 158/4885CYP4A11 75/4885ALDH1A1 708/4885 |
| US-20040249188-A1 | Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide) | ALDH1A1, ADRM1, ALDH7A1 | CYP4F2 908/4885CYP4A11 130/4885ALDH1A1 1/4885 |
| US-20100076027-A1 | INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, ABCB11, FXR1 | CYP4F2 122/4885CYP4A11 72/4885ALDH1A1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.